Back to search

Article

Combining VEGFR tyrosine kinase inhibitors and PD-1/PD-L1 inhibitors versus VEGFR tyrosine kinase inhibitors monotherapy in renal cell carcinoma: a target trial emulation

2026-07-02

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Importance</h4> Combinations of VEGFR tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs), such as antibodies to programmed cell death-1 (PD-1), or to its ligand PD-L1, are now first-line standard of care for renal cell carcinoma (RCC), but the pivotal clinical trials excluded patients with common comorbidities, leaving their real-world effectiveness uncertain. <h4>Obj...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
435fda5e-22db-5b91-8f51-879c54d0a30a
DOI
10.64898/2026.06.30.26356941
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Combining VEGFR tyrosine kinase inhibitors and PD-1/PD-L1 inhibitors versus VEGFR tyrosine kinase inhibitors monotherapy in renal cell carcinoma: a target trial emulationDOI 10.64898/2026.06.30.26356941
Efficacy and safety of anti-VEGF/VEGFR monotherapy and combination with immune checkpoint inhibitors for advanced or metastatic renal cell carcinoma: A network meta-analysisSemantic proximity
Adverse events after nivolumab and ipilimumab combined immunotherapy in advanced renal cell carcinoma: a multicentre experience in PolandSemantic proximity
Anti-Angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-CarcinomaSemantic proximity
Predict progression free survival and overall survival using objective response rate for anti - PD1 / PDL1 therapy developmentSemantic proximity
Enhancing First-Line TKI Efficacy in PD-L1-Positive EGFR-Mutated NSCLC: The Role of Antiangiogenic AgentsSemantic proximity
The implementation of lenvatinib/everolimus or lenvatinib/pembrolizumab combinations in the treatment of metastatic renal cell carcinoma.Semantic proximity
Outcomes of CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma by Race: A Multicenter Real-World StudySemantic proximity
Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial.Semantic proximity
VHL mutations predict survival of patients with renal cell carcinoma in response to the therapy of immune checkpoint inhibitorsSemantic proximity
Aristolochic acid-related renal cell carcinoma exhibits a distinct tumor-immune microenvironment favoring response to immune checkpoint blockade.Semantic proximity
Cabozantinib for Renal Cell Carcinoma: Current and Future Paradigms.Semantic proximity
Predicting Individual Responses in Phase I Oncology Trials Using Routinely Collected Clinical BiomarkersSemantic proximity
Select a neighboring publication to make it the new centre.